CZ20011950A3 - Sloučenina podle obecného vzorce tricyklické sloučeniny, její pouľití, způsob oąetření nádorových buněk, způsob inhibování farnesylproteintransferasy a farmaceutický prostředek - Google Patents

Sloučenina podle obecného vzorce tricyklické sloučeniny, její pouľití, způsob oąetření nádorových buněk, způsob inhibování farnesylproteintransferasy a farmaceutický prostředek Download PDF

Info

Publication number
CZ20011950A3
CZ20011950A3 CZ20011950A CZ20011950A CZ20011950A3 CZ 20011950 A3 CZ20011950 A3 CZ 20011950A3 CZ 20011950 A CZ20011950 A CZ 20011950A CZ 20011950 A CZ20011950 A CZ 20011950A CZ 20011950 A3 CZ20011950 A3 CZ 20011950A3
Authority
CZ
Czechia
Prior art keywords
alkyl
substituted
aryl
compound
arylalkyl
Prior art date
Application number
CZ20011950A
Other languages
Czech (cs)
English (en)
Inventor
Timothy Guzi
Alan K. Mallams
Alan B. Cooper
Ronald J. Doll
Viyyoor M. Girijavallabhan
Arthur G. Taveras
Joseph M. Kelly
Jianping Chao
Dinanath F. Rane
Johan A. Ferreira
Viyyoor M. Han
Adriano Afonso
Cynthia J. Aki
Carmen Alvarez
Tarik Lalwani
Jagdish A. Desai
James J. S. Wang
Jay Weinstein
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CZ20011950A3 publication Critical patent/CZ20011950A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ20011950A 1998-12-18 1999-12-16 Sloučenina podle obecného vzorce tricyklické sloučeniny, její pouľití, způsob oąetření nádorových buněk, způsob inhibování farnesylproteintransferasy a farmaceutický prostředek CZ20011950A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
CZ20011950A3 true CZ20011950A3 (cs) 2001-12-12

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011950A CZ20011950A3 (cs) 1998-12-18 1999-12-16 Sloučenina podle obecného vzorce tricyklické sloučeniny, její pouľití, způsob oąetření nádorových buněk, způsob inhibování farnesylproteintransferasy a farmaceutický prostředek

Country Status (20)

Country Link
EP (1) EP1140902A1 (enExample)
JP (1) JP2002533336A (enExample)
KR (1) KR20010081116A (enExample)
CN (1) CN1326850C (enExample)
AR (1) AR021718A1 (enExample)
AU (1) AU776558B2 (enExample)
BR (1) BR9916314A (enExample)
CA (1) CA2354779A1 (enExample)
CO (1) CO5160350A1 (enExample)
CZ (1) CZ20011950A3 (enExample)
HU (1) HUP0202152A2 (enExample)
IL (1) IL143408A0 (enExample)
NO (1) NO20012961L (enExample)
NZ (1) NZ511878A (enExample)
PE (1) PE20001342A1 (enExample)
PL (1) PL348293A1 (enExample)
SK (1) SK7592001A3 (enExample)
TR (1) TR200101755T2 (enExample)
WO (1) WO2000037459A1 (enExample)
ZA (1) ZA200104233B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
CA2590979A1 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
BR112016021257B1 (pt) * 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
ZA985203B (en) * 1997-06-17 1999-01-05 Schering Corp Compounds useful for inhibition of farnesyl protein transferase
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
PL348293A1 (en) 2002-05-20
IL143408A0 (en) 2002-04-21
SK7592001A3 (en) 2002-03-05
ZA200104233B (en) 2002-08-22
NZ511878A (en) 2003-10-31
KR20010081116A (ko) 2001-08-27
AR021718A1 (es) 2002-07-31
JP2002533336A (ja) 2002-10-08
AU776558B2 (en) 2004-09-16
HUP0202152A2 (en) 2002-10-28
CA2354779A1 (en) 2000-06-29
WO2000037459A1 (en) 2000-06-29
TR200101755T2 (tr) 2001-09-21
EP1140902A1 (en) 2001-10-10
BR9916314A (pt) 2001-10-02
CN1326850C (zh) 2007-07-18
PE20001342A1 (es) 2000-12-09
CO5160350A1 (es) 2002-05-30
AU2030700A (en) 2000-07-12
NO20012961D0 (no) 2001-06-15
NO20012961L (no) 2001-08-16
CN1334811A (zh) 2002-02-06

Similar Documents

Publication Publication Date Title
US6372747B1 (en) Farnesyl protein transferase inhibitors
US6432959B1 (en) Inhibitors of farnesyl-protein transferase
US6362188B1 (en) Farnesyl protein transferase inhibitors
CA2240846C (en) Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
US6300338B1 (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5891872A (en) Tricyclic compounds
EP1140904B1 (en) Farnesyl protein transferase inhibitors
EP0815100A1 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1996030362A1 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
HUP0001109A2 (hu) Triciklusos farnezil-protein transzferáz inhibitorok mint tumorellenes vegyületek
US20030055065A1 (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP0989983B1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
CZ20011950A3 (cs) Sloučenina podle obecného vzorce tricyklické sloučeniny, její pouľití, způsob oąetření nádorových buněk, způsob inhibování farnesylproteintransferasy a farmaceutický prostředek
US6800636B2 (en) Farnesyl protein transferase inhibitors
EP1140909B1 (en) Novel inhibitors of farnesyl-protein transferase
HUP0004521A2 (hu) Farnezil-protein transzferáz inhibitorokként alkalmazható benzo[5,6]-ciklohepta-piridil-(ciklusos karbamid- és laktám)-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
US6528523B2 (en) Farnesyl protein transferase inhibitors
AU2002235143A1 (en) Novel Farnesyl Protein Transferase Inhibitors
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors
SK33999A3 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
SK33299A3 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
MXPA01006611A (en) Novel inhibitors of farnesyl-protein transferase